<u>. </u>					1200 22 1120 20 20 20 1111 21 21 21 20 20 20 20 20 20 20 20 20 20 20 20 20	
S	substitute for form 1449A/PTO)		COMPLETE IF KNOWN		
]	INFORMATIO	N DISCI	LOSURE	Application Number	10/580,183	
	TATEMENT.	DV ADDI	ICAPE	Filing Date	May 22, 2006	
	STATEMENT BY APPLICANT F			First Named Inventor	Emma R. Parmee, et al.	
	(use as many sheets as necessary)	- AUG 1 8 2006	Group Art Unit	To Be Assigned		
	(use as many she	eets as nece	ssary)	Examiner Name	To Be Assigned	
Sheet	1	of	MIBEMASA	Attorney Docket Number	21458P	
						

		*	U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/SY/	1	US 5,719,173		Nishikawa et al	02/17/1998
/SY/	2	US 5,776,954		de Laszlo et al	07/07/1998
/SY/	3	US 6,218,431 B1		Schoen et al	04/17/2001
/SY/	4	US 6,503,949 B1		Lau et al	01/07/2003
	5	US 6,562,807 B2		Jorgensen et al	05/13/2003
ISYI	6	US 6,613,942 B1		Ling et al	09/02/2003
	7	US 6,762,318 B2		Kodra et al	07/13/2004
	_				
		<u> </u>			

			FORE	IGN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	<u> </u>	Foreign Patent Docume		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/SY/	1	PCT	WO 97/16442		Merck & Co., Inc	05/09/1997
/SY/	2	PCT	WO 98/21957		Merck & Co., Inc	05/28/1998
/SY/	3	PCT	WO 98/22108		Merck & Co., Inc	05/28/1998
/SY/	4	PCT	WO 98/22109		Merck & Co., Inc	05/28/1998
/SY/	5	PCT	WO 99/32448		Amgen Inc	07/01/1999
/SY/	6	PCT	WO 00/39088		Novo Nordisk A/S	07/06/2000
/SY/	7	PCT	WO 02/40444 A1		Novo Nordisk A/S	05/23/2002

Examiner | /Shawquia Young/ | Date | Considered | 08/24/2007 |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.